Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03217591 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria
A Phase 2 study, sponsored by Akebia Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT03217591 is a Phase 2 study that has completed, run by Akebia Therapeutics. The registered enrollment target is 156 participants.
The verdict
NCT03217591, a Phase 2 study, has completed, sponsored by Akebia Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.
Interventions
- DRUG Placebo
- DRUG IW-1973
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2019-08-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03217591
The ClinicalTrials.gov registry entry for NCT03217591 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03217591 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03217591 about?
NCT03217591 is a clinical study titled "A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria". To evaluate the safety and efficacy of IW-1973 in patients with type 2 diabetes mellitus with albuminuria who are on a stable regimen of renin-angiotensin system inhibitors.
What is the current status of trial NCT03217591?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2017-08-01. Estimated completion is 2019-08-20.
What interventions are being tested in trial NCT03217591?
The interventions under investigation include: Placebo (DRUG), IW-1973 (DRUG).
Who is sponsoring clinical trial NCT03217591?
This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.